Piramal Pharma Balance Sheet Health
Financial Health criteria checks 3/6
Piramal Pharma has a total shareholder equity of ₹79.1B and total debt of ₹45.6B, which brings its debt-to-equity ratio to 57.6%. Its total assets and total liabilities are ₹153.1B and ₹74.0B respectively. Piramal Pharma's EBIT is ₹4.6B making its interest coverage ratio 1.1. It has cash and short-term investments of ₹5.0B.
Key information
57.6%
Debt to equity ratio
₹45.59b
Debt
Interest coverage ratio | 1.1x |
Cash | ₹5.02b |
Equity | ₹79.11b |
Total liabilities | ₹74.00b |
Total assets | ₹153.12b |
Recent financial health updates
Recent updates
Here's Why Piramal Pharma (NSE:PPLPHARMA) Has A Meaningful Debt Burden
Jul 14Estimating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Jun 17We Think That There Are Issues Underlying Piramal Pharma's (NSE:PPLPHARMA) Earnings
May 21It's A Story Of Risk Vs Reward With Piramal Pharma Limited (NSE:PPLPHARMA)
Mar 26Estimating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Feb 28Earnings Update: Here's Why Analysts Just Lifted Their Piramal Pharma Limited (NSE:PPLPHARMA) Price Target To ₹161
Feb 02Calculating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Nov 09Calculating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Aug 11Financial Position Analysis
Short Term Liabilities: PPLPHARMA's short term assets (₹54.6B) exceed its short term liabilities (₹43.7B).
Long Term Liabilities: PPLPHARMA's short term assets (₹54.6B) exceed its long term liabilities (₹30.3B).
Debt to Equity History and Analysis
Debt Level: PPLPHARMA's net debt to equity ratio (51.3%) is considered high.
Reducing Debt: Insufficient data to determine if PPLPHARMA's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: PPLPHARMA's debt is well covered by operating cash flow (22%).
Interest Coverage: PPLPHARMA's interest payments on its debt are not well covered by EBIT (1.1x coverage).